CD274 and non-small cell lung carcinoma: Particularly, in a recent first-line trial, pembrolizumab was associated with significantly longer progression-free and overall survival than platinum-based chemotherapy in patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells.